Analysts' recommendations: Alzinova AB

06-24	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
04-08	RX Securities sees potential upside for Alzinova from Alzheimer's diagnostic collaboration	FW
03-26	DNB Carnegie sees reduced financing risk for Alzinova, but partnership remains critical	FW
06/10/25	Alzinova gets fast track designation from US FDA	RE
06/10/25	Alzinova's Alzheimer's Disease Vaccine Candidate Gets Fast-track Designation from US FDA	MT

More recommendations

Managers and Directors: Alzinova AB

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	30/09/2024
Anders Sandberg COO	Chief Operating Officer	54	16/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	26/03/2024

Director	Title	Age	Since
Anders Waas BRD	Director/Board Member	69	31/12/2017
Per-Göran Gillberg BRD	Director/Board Member	70	31/12/2019
Julian Aleksov CHM	Chairman	61	31/12/2022

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	+26.19%	+58.45%	-39.84%	-68.64%	17.55M
LONZA GROUP AG	+2.08%	-1.48%	-1.34%	+14.07%	46.86B
REVOLUTION MEDICINES, INC.	-0.61%	+1.03%	+396.16%	+643.07%	40.23B
BEONE MEDICINES AG	0.00%	+4.45%	+11.81%	+60.81%	36.23B
IQVIA HOLDINGS INC.	+2.48%	+3.37%	+7.05%	-8.08%	34.72B
CELLTRION, INC.	+0.62%	+1.65%	+5.41%	+43.89%	27.89B
MEDPACE HOLDINGS, INC.	-2.00%	+9.60%	+31.71%	+129.76%	16.79B
ASCENDIS PHARMA A/S	-0.17%	-2.90%	-	-	16.74B
EUROFINS SCIENTIFIC SE	+0.78%	-4.78%	-2.68%	+9.96%	13.12B
ICON PUBLIC LIMITED COMPANY	+1.82%	-0.72%	-9.75%	-33.31%	12.7B
Average	+3.12%	+3.43%	+44.28%	+87.95%	24.53B
Weighted average by Cap.	+0.71%	+1.06%	+74.69%	+138.09%

See all sector performances

Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

08-20 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
27/07/26	SEK 1.060	+26.19%	8,929,009
24/07/26	SEK 0.8400	+12.00%	3,016,369
23/07/26	SEK 0.7500	+7.45%	2,704,804
22/07/26	SEK 0.6980	+5.76%	5,698,218
21/07/26	SEK 0.6600	+0.15%	1,924,520

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 27/07/2026 BST			5-day change	1st Jan Change
1.060 ^SEK	+26.19%		+58.45%	+27.86%

Market Cap	215M 22.09M 19.43M 18.09M 16.63M 31.22M 2.12B 31.62M 83.88M 1.05B 82.91M 81.12M 3.65B	P/E 2026 *	-3.93x	P/E 2027 *	-2.79x
Enterprise Value	199M 20.44M 17.98M 16.75M 15.39M 28.9M 1.96B 29.27M 77.63M 969M 76.73M 75.08M 3.38B	EV / Sales 2026 *	6.34x	EV / Sales 2027 *	-
Free-Float	82.23%	Yield 2026 *	-	Yield 2027 *	-

06-24	Alzinova AB and Fujirebio Enter Letter of Intent for Potential Commercialization of Blood-Based Alzheimer?S Diagnostic Test	CI
06-24	Alzinova Inks Nonbinding Deal with Fujirebio for Potential Alzheimer's Blood-based Diagnostic Test	MT
06-24	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
06-24	Alzinova signs non-binding letter of intent with Fujirebio on Alzheimer's diagnostics	FW
06-12	Alzinova raises SEK15.3m from warrants: underwriting not required	FW
06-08	Alzinova raises SEK 15.2 million before issuance costs	FW
05-26	Calendar Tuesday May 26	FW
05-25	Calendar Tuesday May 26	FW
05-21	Alzinova secures 80 percent of TO4 warrants	FW
05-20	Alzinova phase 1b results published in scientific journal	FW
05-20	Alzinova AB Publishes Clinical Results with ALZ-101 in Alzheimer?s Research & Therapy	CI
05-13	Alzinova AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Alzinova Q1 loss after financial items SEK 6 mln	RE

07-07	BioVal™ analysis of Alzinova's ALZ-101 – rNPV of SEK 7.1B	AQ
06-24	Alzinova: Newsflow update – diagnostic optionality and TO4 proceeds	AQ
06-24	Alzinova signs Letter of Intent with Fujirebio regarding potential commercialization of blood-based Alzheimer’s diagnostic test	AQ
06-12	Warrants of series TO4 were exercised to approximately 94.2 percent and the Company will receive approximately 15.3 million	AQ
06-08	Alzinova announces preliminary outcome of the exercise of warrants of series TO4	AQ

1 day	+26.19%
1 week	+58.45%
Current month	+113.71%
1 month	+94.50%
3 months	+133.48%
6 months	+34.18%
Current year	+27.86%

Alzinova AB Share Price

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation: Alzinova AB

Chart: Alzinova AB

Latest news : Alzinova AB

Analysts' recommendations: Alzinova AB

Press Releases: Alzinova AB

Quotes and Performance

Course Extremes

Managers and Directors: Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	0.61	1.1
1 month	0.48	1.61
Current year	0.38	1.61
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	8.7
10 years	0.38	44.9

	2026 *	2027 *
Net sales	31.35M 3.22M 2.84M 2.64M 2.43M 4.56M 309M 4.62M 12.24M 153M 12.1M 11.84M 532M	-
Net income	-3.2M -329K -289K -270K -248K -465K -31.55M -471K -1.25M -15.6M -1.24M -1.21M -54.34M	-50.35M -5.18M -4.55M -4.24M -3.9M -7.32M -496M -7.41M -19.66M -245M -19.43M -19.01M -855M
Net Debt	-16M -1.65M -1.45M -1.35M -1.24M -2.33M -158M -2.36M -6.25M -77.99M -6.18M -6.04M -272M	-19M -1.95M -1.72M -1.6M -1.47M -2.76M -187M -2.8M -7.42M -92.61M -7.33M -7.18M -323M